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Different biological activities of Hypericum perforatum L. dry extract was tested in this study. An-
tioxidant activity was evaluated by four different assays. Antineurodegenerative activity was tested
using acetylcholinesterase (AChE) and tyrosinase inhibitory activity assays. In all four antioxidant
assays, concentration dependent manner was noticed in the activity of tested extract. The most active
was the highest applied concentration (500 µg/ml). In DPPH test, extract applied in concentration of
200 µg/ml showed similar or higher radical scavenging activity compared to the concentration of 100
µg/ml applied for standard substances BHA and BHT. The lowest antioxidant activity for the extract
was detected in ABTS test. All applied concentrations of dry extract were significantly more potent
than vitamin C in β-carotene test. Moreover, the extract reached 40.31 and 45.56% of the inhibition in
AChE and TYR assays, respectively. In both cases, the most active concentration of the extract was 200
µg/ml.
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1. INTRODUCTION
Hypericaceae includes 8 genera, with about 360 species,
but only Hypericum perforatum (St. John’s wort) is officially
accepted for its positive pharmacological activities. It is
included in European Pharmacopoeia 8.0 as well as in
monographs of the European Medicines Agency, World
Health Organization or European Scientific Association for
Phytotherapy (Ph.Eur.8.0., 2014; EMA, 2009; WHO, 2002;
ESCOP, 2003). Flowering aerial parts of St. John’s wort have
been commonly used in a form of tea, hydroalcoholic extracts
or oil extracts, while standardized, dry hydroalcoholic extracts
are used for the preparation of herbal products, i.e. capsule.
Mainly, such solid preparations are recommended in the
treatment of mild to moderate depressive episode (Butterweck
and Schmidt, 2007). Moreover, St. John’s wort has been
used traditionally for the treatment of mild gastrointestinal
complaints and stomach ulcer, or externally as oil extract for
skin problems and wound healing agent (Miller et al., 1993;
Tucakov, 1996). Chemical composition of H. perforatum is very
complex and the several groups of compounds are considered
as the active principles, i.e. naphthodianthrone derivatives
hypericin and pseudohypericin, phloroglucinol derivatives
hyperforin and adhyperforin, flavonoids and xanthones
(Del Monte et al., 2015; Zdunic´ et al., 2017; WHO, 2002). Those
compounds are connected with variety of biological activities
such as antibacterial, antioxidant, antiviral, antiinlammatory
(Šavikin et al., 2007; Zdunic´ et al., 2009; Saddiqe et al., 2010;
Zdunic´ et al., 2017). Moreover, H. perforatum extract is proved
to be an antidepressant for the treatment of depression with
less side effects then synthetic drugs (Volz, 1997; Peron et al.,
2013). Also, it is considered as neuroprotective agent that
can prevent neurodegenerative pathologies by regulating
neurotransmitter release in animal model, as well as by its
antioxidant and antiinflammatory activity (Grundmann et al.,
2010; Jungke et al., 2011; Klusa et al., 2001).
The aim of this work was to study antioxidant and an-
tineurodegenerative properties of St. John’s-wort dry extract
obtained for commercial purposes in the Production Sector of
the Institute for Medicinal Plant Research “Dr. Josif Pancˇic´”.
2. MATERIALS AND METHODS
1. Plant material
St. John’s-wort dry extract (4-6.5 : 1) was obtained from Pro-
duction Sector of the Institute for Medicinal Plant Research
“Dr. Josif Pancˇic´”. Extraction was done using 60% EtOH. Ex-
tract was brown colored powder, with 5% percentage of mois-
ture, 0.3 mm degree of fragmentation and it contained 0.14% of
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hypericin. The amount of hypericin was analyzed according
to Ph. Eur. 8 and the amount corresponded to the require-
ment. Also, the amount of total phenolics was 58.11±0.94mg
GAE/g (Singleton and Rossi, 1965) while the amount of total
flavonoids was 28.55±0.65mg QE/g (Park et al., 1997).
2. Evaluation of antioxidant activity
2.1. DPPH assay
The scavenging activity of extract was evaluated using 2.2-
dyphenyl-1-picrylhydrazyl (DPPH) assay (Blois, 1958) with
slight modifications. One hundred µL of extract solutions in
methanol (concentrations of 100, 200 and 500 µg/mL) and
900 µL of methanolic solution of DPPH (40 µg/mL) were
mixed. BHA, BHT and ascorbic acid in concentrations of 50
and 100 µg/mL were used as positive controls (standards).
Methanol was used as a blank, while control was prepared to
contain methanol instead of extract/standard. Absorbance of
the reaction mixture was measured after 30 minutes in the dark
at room temperature at 517 nm. The decrease of absorption of
DPPH radical at 517 nm was calculated using equation:
Inhibition of DPPH radical (%) =
AC− AS
AC
x100%
, where AC is the absorbance of control (without test sam-
ple) and AS is the absorbance of the test sample at different
concentrations.
All experimental measurements were carried out in tripli-
cate and the results are expressed as average of three measure-
ments ± standard deviation.
2.2. ABTS assay
The scavenging activity of extract was evaluated using ABTS
assay using procedure of Miller et al. (1993) with some modi-
fications. Stock ABTS+ solution (7 mM) was prepared 12-16
hours before experiment in 2.46 mM potassium-persulfate and
stored in the dark at room temperature, and then diluted by
distilled water to obtain an absorbance of working solution
0.700 ± 0.020 at 734 nm. Extract solutions in methanol (25 µL)
in concentrations of 100, 200 and 500 µg/mL were mixed with
1 mL of working ABTS+ solution and incubated for 30 min at
30ºC. The same procedure was applied for positive controls
BHA, BHT and ascorbic acid in concentrations of 50 and 100
µg/mL. Absorbance was recorded at 734 nm, and distilled wa-
ter was used as blank, while control contained distilled water
instead of sample. The decrease of ABTS radical absorption at
734 nm was calculated using equation:
Inhibition of ABTS radical (%) =
AC− AS
AC
x100%
, where AC is the absorbance of control (without test sample)
and AS is the absorbance of the test sample at different con-
centrations. All experimental measurements were carried out
in triplicate and the results are expressed as average of three
measurements ± standard deviation.
2.3. Ferric-reducing ability of plasma (FRAP) assay
Ferric-reducing ability of plasma (FRAP) assay evaluates to-
tal antioxidant power of the sample using reduction of fer-
ric tripyridyltriazine (Fe(III)-TPTZ) complex to the ferrous
tripyridyltriazine (Fe(II)-TPTZ) by a test sample at low pH.
The FRAP assay was performed according to Benzie and Strain
(1996) procedure with slight modifications. FRAP reagent
was prepared freshly to contain sodium acetate buffer (300
mmol/L, pH 3.6), 10 mmol/L TPTZ in 40 mmol/L HCl and
FeCl3 x 6H2O solution (20 mmol/L), i.e. in proportion 10:1:1
(v/v/v), respectively. Working FRAP solution was warmed
to 37°C prior to use. Extract solutions in methanol (40 µL) in
concentrations of 100, 200 and 500 µg/mL were added to 1200
µL of FRAP reagent and absorbance was recorded at 593 nm
after 4 minutes. BHA, BHT and ascorbic acid (in concentra-
tions of 50 and 100 µg/mL) were used as standards. Distilled
water was used as blank, while control was prepared to con-
tain distilled water instead of extract. The same procedure
was repeated for standard solution of FeSO4 x 7H2O (0.2-1.6
mmol/L) in order to construct calibration curve. FRAP val-
ues of sample was calculated from standard curve equation
and expressed as µmol FeSO4 x 7H2O/g dry extract. All ex-
perimental measurements were carried out in triplicate and
the results are expressed as average of three measurements ±
standard deviation.
2.4. β-carotene bleaching (ß-CB) assay
β-carotene bleaching assay, designed to evaluate the capacity
of the antioxidants to reduce the oxidative loss of β-carotene in
a β-carotene linoleic acid emulsion, was performed according
to slightly modified procedure of Dapkevicius et al. (1998).
β-carotene (1 mg), linoleic acid (50 µL) and Tween 40 (400
mg) were dissolved in 2 mL of chloroform. Chloroform was
removed using a rotary evaporator at 40°C, and 200 mL of
distilled water was added with vigorous shaking. The solu-
tions of extract (100, 200 and 500 µg/mL) and positive controls
BHA, BHT and ascorbic acid (50 and 100 µg/mL) were pre-
pared in methanol. Aliquots of 1000 µL of the emulsion and
140 µL of sample (extract/standard) were mixed. Distilled
water was used as blank, while control contained distilled
water instead of sample. The absorbances were measured
immediately (t=0 min) and after 2 h incubation (t=120 min) at
490. The antioxidant activity of the sample was evaluated in
terms of inhibition of β-carotene bleaching using the following
equation:
% Inhibition =
A120− C120
C0− C120 x100%
, where A120 and C120 are the absorbances measured in t=120
minutes for sample and control, respectively, while C0 is ab-
sorbance of control in t=0 min. All experimental measure-
ments were carried out in triplicate and the results are ex-
pressed as average of three measurements ± standard devia-
tion.
3. Evaluation of antineurodegenerative activities
3.1. Acethylacholinesterase (AChE) inhibitory activity assay
AChE inhibitory activity assay was performed according to
spectrophotometric method (Ellman et al., 1961) using 96-well
plates as described befor (Orhan et al., 2012) with slight mod-
ifications. The AChE activity was measured by monitoring
of increase of yellow color produced from tiocholine when it
reacts with DTNB ion. The test reaction mixture (S) was pre-
pared by adding 140 µL of sodium phosphate buffer (0.1 M,
pH 7.0), 20 µL of DTNB, 20 µL of extract-buffer solution con-
taining 5% DMSO (concentration of 100, 200 and 500 µg/mL)
and 20 µL of AChE solution (5 units/mL). The mixture with-
out extract was used as the control (C), while blank (B) did not
contain AChE solution. The commercial anticholinesterase
alkaloid-type of drug galanthamine was used as reference.
After incubation (15 min, 25°C), the reaction was initiated
with the addition of 10 µL of acetylthiocholine iodide and ab-
sorbance was measured at wavelength of 412 nm using Tecan
Sunrise SN microplate reader equipped by XFluor4 software.
Percentage of inhibition of AChE by sample was determined
using the formula:
Inhibition of AChE (%) =
C− (S− B)
C
x100%
All experimental measurements were carried out in triplicate
and the results are expressed as average of three measure-
ments ± standard deviation.
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Table 1. Antioxidant activity of St John’s-wort dry extract
Sample Concentration
DPPH radical
scavengy
activitya
ABTS radical
scavengy activity FRAP activity
β-carotene
bleaching activity
(µg/mL) % of inhibition % of inhibition µmol Fe(II)/g % of inhibition
SJW dry extract 100 25.50±0.69a 12.94±0.73a 193.03±5.71a 23.68±1.02a
200 44.69±0.39b 22.83±0.75b 361.98±3.80b 29.99±1.36b
500 87.80±0.64c 48.13±0.80c 663.76±7.78c 59.85±1.94c
BHA 50 28.21±0.60d 56.18±0.80d 231.22±4.71a 50.79±2.76d
100 43.33±0.87b 64.95±0.63e 572.85±5.71d 57.70±1.91c
BHT 50 20.86±0.81e 37.47±0.67f 364.05±5.62b 48.74±1.79d
100 34.31±0.43f 55.11±0.44d 413.03±3.13be 56.29±1.44c
Vit C 50 58.99±1.01g 35.14±0.58g 427.56±5.18e 1.73±1.19e
100 91.65±0.21h 55.70±0.69d 576.17±7.61d 2.99±2.13e
aValues with the same letter (a-h) in each column showed no statistically significant difference (P <0.05); Statistical analysis was based on a
one-way ANOVA and Bonferroni tests.
3.2. Tyrosinase inhibitory activity assay
Tyrosinase inhibitory activity assay was performed according
to slightly modified spectrophotometric method of Masuda
et al. (2005) using 96-well plates. Samples (extract and stan-
dard kojic acid) were dissolved in sodium phosphate buffer
(0.1 M, pH 7.0) containing 5% DMSO and phosphate buffer,
respectively, in concentration of 100, 200 and 500 µg/mL. The
wells were designed as: A (containing 120 µL of sodium buffer
and 40 µL of tyrosinase in the same buffer (46 units/L), B
(containing only buffer), C (containing 80 µL of buffer, 40 µL
of tyrosinase and 40 µL of sample) and D (containing 120 µL
of buffer and 40 µL of sample). After addition of 40 µL of
L-DOPA and incubation (30 min, 25°C), absorbance was mea-
sured at 475 nm using Tecan Sunrise SN microplate reader
equipped by XFluor4 software. Percentage of inhibition of
tyrosinase was determined using the formula:
Inhibition of tyrosinase (%) =
(A− B)− (C− D)
(A− B) x100%
All experimental measurements were carried out in triplicate
and the results are expressed as average of three measure-
ments ± standard deviation.
4. Statistical analysis
Results are presented as the mean value ± standard deviation
of three independent replicate experiments (n = 3). Statistical
analysis was based on a one-way ANOVA test.Statistically
significant effects were further analyzed and means were com-
pared using Bonferroni test. A level of P<0.05 was taken as
statistically significant.
3. RESULTS AND DISCUSSION
1. Evaluation of antioxidant activity
Antioxidant activity of St. John’s-wort dry extract was mea-
sured using four parallel tests and the results are presented in
Table 1. Extract was tested in three concentrations (100, 200
and 500 µg/ml), while standard substances BHA, BHT and
ascorbic acids, in concentrations of 50 and 100 µg/ml.
In all four assays, concentration dependent manner was no-
ticed in the activity of tested extract. The most active was the
highest applied concentration of 500 µg/ml. In DPPH test,
extract applied in concentration of 200 µg/ml showed similar
or better radical scavenging activity compared to the concen-
tration of 100 µg/ml applied for standard substances BHA
and BHT . The lowest antioxidant activity for the extract was
detected in ABTS test. Considering FRAP assay, only concen-
tration of extract of 500 µg/ml was more active (663.76 µmol
Fe(II)/g) compared to the tested standard substances applied
in concentration of 100 µg/ml. Similar was in ß-carotene test,
but taking into account vitamin C, all applied concentrations
of dry extract were significantly more potent than that stan-
dard substance in 100 µg/ml.
Del Monte et al. (2015) reported higher DPPH radical scav-
enging activity of extracts they analyzed compared to our
extract. Briefly, methanol and chloroform–methanol extracts
they analyzed showed 73.07% and 77.23% of scavenging ac-
tivity, respectively but, chloroform extract did not exhibit
DPPH scavenging activity (IC50 more than 100 µl). This differ-
ence is probably due to different solvents used in their study
(methanol and chloroform–methanol)compared to 60% EtOH
in our. Moreover, Heydarian et al. (2017), showed that crude
polysaccharides extracted from St John’s-wort have DPPH
and OH free radicals scavenging activity.
1.1. Evaluation of antineurodegenerative activities
Enzyme inhibition activity of St. John’s-wort dry extract was
tested against two enzymes, acetylcholinesterase (AChE) and
tyrosinase (TYR), which are connected with development of
the different neurodegenerative disorders. Loss of memory
that occurs in Alzheimer’s disease (AD) is characterized by re-
duced level of neurotransmitter acetylcholine. Consequently,
cholinesterase inhibitors are proved to be effective in treating
patients suffering of mild to moderately level of AD (Ahmed
et al., 2013). Tyrosinase, a key enzyme in the synthesis of
melanin, is also involved in the formation of neuromelanin
which hyperproduction is associated with Parkinson’s dis-
ease (PD) (Greggio et al., 2005). The current therapy for neu-
rodegenerative diseases dominantly reduce progression of the
disease but do not lead to complete cure. Also, such ther-
apy is often accompanied by side effects. Plants or natural
products which could prevent, slow down or cure various
disorders, including neurodegenerative diseases are of great
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Table 2. Antineurodegenerative activity of St John’s-wort dry extract
Concentration (µg/mL) AChE inhibitory activitya Tyr inhibitory activity
% of inhibition % of inhibition
SJW dry extract 100 35.44±1.01ab 41.08±4.60a
200 40.31±4.73a 45.56±0.60ab
500 31.32±2.22b 43.87±2.51a
Galanthamine 100 57.11±1.68c -
Kojic acid 100 - 51.81±2.55b
aValues are means ± standard deviation. n = 3; Mean values within a column with different letters are significantly different at P<0.05; Statistical
analysis was based on a one-way ANOVA and Bonferroni tests.
interest (Morzelle et al., 2016).
In our study, three concentrations (100, 200 and 500 µg/ml)
of St. John’s-wort dry extract were tested in AChE and TYR
inhibition assays and compared with the activity of 100 µg/ml
reference drugs galanthamine and kojic acid, respectively (Ta-
ble 2). Both standard substances achieved an inhibition of
over 50% at the concentration of 100 µg/ml, while our extract
reached 40.31 and 45.56% in AChE and TYR assays, respec-
tively. In both cases, the most active was concentration of 200
µg/ml of extract.
Although antineurodegenerative activities of H. perforatum
extract were evaluated as weaker comparing to standards, it
could be connected to the type of extragens applied for the
production of extract.
Hernandez et al. (2010) tested water extracts of three Hyper-
icum species from Portugal on AChE inhibitory activity and
all species possessed activity but the lowest were detected for
the extract of H. perforatum. Moreover, Cao et al. (2017) re-
ported neuroprotective activity of 80% ethanolic H. perforatum
extract against AlCl3-induced AD like pathology in rats. They
concluded that beneficial effect of the extract could be due to
its known antioxidant and anti-inflammatory activities.
CONCLUSION
In the present study, the results for antioxidant and antineu-
rodegenerative activities of St. John’s-wort dry extract are
presented. The highest antioxidant activity has been noticed
in DPPH test while the weakest was in ABTS test. All applied
concentrations of dry extract were significantly more potent
than vitamin C in β-carotene test. Antineurodegenerative ac-
tivities of H. perforatum extract were evaluated as moderate.
Future research will be focused on extraction optimization
aimed to enrich the extract with compounds that could con-
tribute to AChE and TYR inhibitory activities.
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